Experts Say Latest Reverse Payments Could Lead to High Court Action

(Bloomberg Bureau of National Affairs)  In an opinion that could very well be a game-changer for drug companies involved in antitrust cases challenging the legality of patent litigation settlements, a federal judge Nov. 5 ruled that a 2013 U.S. Supreme Court holding doesn’t bar the door to testimony about the strength of the patent underlying a challenged settlement (King Drug Co. of Florence, Inc. v. Cephalon, Inc., E.D. Pa., No. 2:06-cv-01797-MSG, Nov. 5, 2015).

Read The Full Article